comprehensive -WSS

comprehensive

author：focus 2025-10-02 18:48:10 - browse：56748

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

entertainment

WSS

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Roivant's CEO is a star, but biotech's black hole persists

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Roche drug slashes death risk in early

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

explore

comprehensive

hotspot

Virginia high school admissions case could be legal follow

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Psychedelics group wrestles with new pharma identity

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Dobbs anniversary: the lost opportunity of abortion as health care

Ionis drug prevents swelling attacks due to hereditary angioedema

Wildfire smoke exposes gaps in outdoor worker protections

HIV drugs protect against transmission, even in unprotected sex

New air purifier tech could be key to improving indoor air quality

NIH documents show early flaws of $1.6 billion long Covid program

hotspot

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Readout LOUD podcast: Live from the 2023 STAT Summit

Ultragenyx gene therapy for rare liver ailment succeeds in late

ADCs take center stage as promising cancer treatments

The problems with dementia villages

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

focus

entertainment

hotspot

Wikipedia